Clinical trials
Researchers at the University of Health Sciences in Ankara, Turkiye, have made a significant discovery in clinical trial research. By analyzing serum b-hCG values, they found that these values can predict live birth in both fresh and frozen embryo transfers with a sensitivity of 75% and a specificity of 72%
Clinical trials
Sanofi has scrapped its respiratory syncytial virus (RSV) vaccine for toddlers, dubbed SP0125, after an independent data monitoring committee (IDMC) determined that it was unlikely to demonstrate suitable efficacy in a late-stage study. The intranasal live attenuated vaccine was being evaluated in a phase 3 study involving approximately 6,300
Clinical trials
Sanofi has scrapped its respiratory syncytial virus (RSV) vaccine for toddlers, dubbed SP0125, after an independent data monitoring committee (IDMC) determined that it was unlikely to demonstrate suitable efficacy in a late-stage study. The intranasal live attenuated vaccine was being evaluated in a phase 3 study involving approximately 6,300
Clinical trials
As of October 20, 2025, DelveInsight's comprehensive Essential Tremor Pipeline Insight report highlights the dynamic pipeline landscape, featuring 7+ companies and 10+ pipeline drugs being developed for the treatment of essential tremor. The report provides an in-depth analysis of the pipeline therapies, including their mechanism of action, clinical
Business research
As of October 20, 2025, DelveInsight's comprehensive Essential Tremor Pipeline Insight report highlights the dynamic pipeline landscape, featuring 7+ companies and 10+ pipeline drugs being developed for the treatment of essential tremor. The report provides an in-depth analysis of the pipeline therapies, including their mechanism of action, clinical
Associations
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, has presented positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the European Society of Medical Oncologists meeting in Berlin, Germany. The data highlights the potential value of combination
Biological pest control
Research published in Forest Ecology and Management has demonstrated the efficacy of Phlebiopsis gigantea as a biocontrol agent against Heterobasidion irregulare, a root disease affecting coniferous forests in the Pacific western US. The study, conducted by a team of researchers from the University of California Berkeley, evaluated the growth and
Clinical trials
Researchers have made significant strides in understanding the nature of voice hearing, shifting from a medical view of it as a psychotic symptom to a dissociative experience. Historically, voice hearing was classified as a core symptom of schizophrenia in the late 20th century, but an alternative paradigm emerged through the
Artificial intelligence
Artificial intelligence is revolutionizing the field of clinical research and scientific writing, offering innovative solutions to address inefficiencies in trial design, patient recruitment, and manuscript development. Research from Yale University School of Medicine has explored the applications of artificial intelligence in patient matching, endpoint design and predictive trial outcomes, and
Clinical trials
Researchers at the Ifakara Health Institute have reported new data on malaria surveillance methods, highlighting the need for new technologies and approaches to collect data and design control tools. The study utilized digital technologies, including the HumBug acoustic sensor and the MozzWear app, to detect and identify host-seeking mosquitoes. A
Clinical trials
Oncoinvent ASA, a clinical-stage radiopharmaceutical company, has announced positive final 24-month follow-up results from its Phase 1 clinical trial evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The trial aimed to eliminate post-surgery micro-metastases and prevent or delay peritoneal recurrence using direct intraperitoneal targeting with the
Autoimmunity
AbelZeta Pharma, a global clinical-stage biopharmaceutical company, announced that clinical data from the first-in-human Phase I trial of C-CAR168 in patients with refractory autoimmune diseases will be presented at the American College of Rheumatology (ACR) Convergence 2025. The presentation will highlight the potential of C-CAR168 to simultaneously target autoantibody-producing plasma
